In response

Annals of Internal Medicine

Volumn 163, Issue 3, 2015, Pages 242-243

  Cornell, John E ^a   Mulrow, Cynthia D ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PCSK9 ANTIBODY; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; SERINE PROTEINASE;

CARDIOVASCULAR MORTALITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LETTER; META ANALYSIS (TOPIC); MORBIDITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; FEMALE; IMMUNOLOGY; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84938808791     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L1551183     Document Type: Letter

References (3)

1. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351-75. [PMID: 15116347]
2. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration. 2011. Accessed at www.cochrane-handbook.org on 6 June 2015.
3. Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E. PCSK9 inhibitors: a new era in lipid-lowering treatment? Ann Intern Med. 2015;163: 64-5. [PMID: 25915768] doi:10.7326/M15-0920